|
Dec 22
|
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
|
|
Dec 21
|
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
|
|
Dec 20
|
Vertex Pharmaceuticals (VRTX) Stock Moves -0.72%: What You Should Know
|
|
Dec 20
|
Bluebird Bio Stock Is in Free Fall Weeks After a Landmark FDA Approval. Here’s Why.
|
|
Dec 20
|
12 Most Promising Gene Editing Stocks According to Hedge Funds
|
|
Dec 19
|
Crispr Therapeutics Medical Chief Morrow to Resign
|
|
Dec 19
|
Charles River's (CRL) Memphis Site Achieves Crucial Approval
|
|
Dec 19
|
The Zacks Analyst Blog Highlights Novo Nordisk, Eli Lilly, Vertex Pharmaceuticals, Regeneron and GSK
|
|
Dec 18
|
Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
|
|
Dec 18
|
Vertex (VRTX), CRISPR Get Positive CHMP Opinion for Gene-Therapy
|
|
Dec 18
|
5 Big Drug Stocks That May Continue to Outperform in 2024
|
|
Dec 18
|
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
|
|
Dec 14
|
Vertex Pharmaceuticals: Growth Is Still a Better Choice
|
|
Dec 14
|
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
|
|
Dec 14
|
Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
|
|
Dec 14
|
Vertex (VRTX) Soars 13.2%: Is Further Upside Left in the Stock?
|
|
Dec 13
|
S&P 500 Gains and Losses Today: Regional Banks Get a Boost From the Fed
|
|
Dec 13
|
Vertex Pharmaceuticals, Canopy, US Steel: Trending Stocks
|
|
Dec 13
|
Vertex Stock Breaks Out On Phase 2 Results For Opioid Alternative
|
|
Dec 13
|
Vertex Breaks Out To Record High As It Takes On Opioids In Pain Treatment
|